论文部分内容阅读
目的:探讨肝癌患者术后早期应用胸腺肽α1对T淋巴细胞亚群的影响。方法:46例肝癌手术患者,随机分治疗组(23例)和对照组(23例),治疗组于术后1、3、5 d皮下注射胸腺肽α1 1.6 mg,观察2组术前后第1、4、7 d CD3+、CD4+、CD8+、CD4+/CD8+的变化情况。结果:(1)组内比较:对照组术后CD4+、CD4+/CD8+低于术前(P<0.05),术后第1、4、7 d CD8+高于手术前(P<0.05)。治疗组CD3+、CD4+、CD4+/CD8+术后与术前相比无显著差异;CD3+、CD4+/CD8+术后第1、7 d比较有显著差异(P<0.05)。(2)组间比较:CD4+、CD4+/CD8+治疗组高于对照组(术后第1、4、7 d均P<0.05),治疗组CD8+细胞百分率低于对照组(术后第1、4、7 d均P<0.05);治疗组CD3+细胞百分率高于对照组(术后第4、7 dP<0.05)。结论:手术对肝癌患者术后T淋巴细胞免疫功能有抑制作用,胸腺肽α1对T淋巴细胞免疫功能有调节作用。
Objective: To investigate the effect of early application of thymosin α1 on T lymphocyte subsets in patients with liver cancer. Methods: Forty-six patients with hepatocellular carcinoma (HCC) were randomly divided into treatment group (23 cases) and control group (23 cases). Thymosin α1 1.6 mg was injected subcutaneously in the treatment group at 1, 3 and 5 days after operation. , 4, 7 d CD3 +, CD4 +, CD8 +, CD4 + / CD8 + changes. Results: (1) The intra-group comparison: The CD4 + and CD4 + / CD8 + levels in the control group were significantly lower than those before the operation (P <0.05). There was no significant difference in the levels of CD3 +, CD4 +, CD4 + / CD8 + between the two groups at the first and seventh day after operation (P <0.05). (2) The comparison of the two groups: The CD4 +, CD4 + / CD8 + treatment group was higher than the control group (all P <0.05 on the 1st, 4th and 7th days after operation), the percentage of CD8 + cells in the treatment group was lower than that in the control group , P <0.05 on day 7). The percentage of CD3 + cells in the treatment group was higher than that in the control group (P <0.05 on the 4th and seventh day after operation). Conclusion: Surgery can inhibit the immune function of T lymphocytes in patients with hepatocellular carcinoma. Thymosin α1 can regulate the immune function of T lymphocytes.